Pfizer 2013 Annual Report Download - page 120

Download and view the complete annual report

Please find page 120 of the 2013 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 123

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123

Quarterly Consolidated Financial Data (Unaudited)
Pfizer Inc. and Subsidiary Companies
2013 Financial Report
119
Quarter
(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA) First Second Third Fourth
2013
Revenues $12,410 $12,973 $12,643 $13,558
Costs and expenses(a) 8,554 7,433 8,837 9,862
Restructuring charges and certain acquisition-related costs(b) 131 183 233 635
Income from continuing operations before provision for taxes on income 3,725 5,357 3,573 3,061
Provision for taxes on income 1,109 1,782 985 430
Income from continuing operations 2,616 3,575 2,588 2,631
Discontinued operations—net of tax(c) 149 10,559 11 (57)
Net income before allocation to noncontrolling interests 2,765 14,134 2,599 2,574
Less: Net income attributable to noncontrolling interests 15 39 96
Net income attributable to Pfizer Inc. $2,750 $14,095 $2,590 $2,568
Earnings per common share—basic:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $0.36 $0.51 $0.39 $0.41
Discontinued operations—net of tax 0.02 1.50 —(0.01)
Net income attributable to Pfizer Inc. common shareholders $0.38 $2.00 $0.39 $0.40
Earnings per common share—diluted:
Income from continuing operations attributable to Pfizer Inc. common
shareholders $0.36 $0.50 $0.39 $0.40
Discontinued operations—net of tax 0.02 1.48 —(0.01)
Net income attributable to Pfizer Inc. common shareholders $0.38 $1.98 $0.39 $0.39
Cash dividends paid per common share $0.24 $0.24 $0.24 $0.24
Stock prices
High $28.90 $31.15 $30.43 $32.50
Low $25.33 $27.12 $27.33 $28.02
(a) The fourth quarter of 2013 reflects historically higher fourth quarter costs in Cost of sales, Selling, informational and administrative expenses and Research and
development expenses.
(b) The fourth quarter of 2013 reflects higher employee termination costs.
(c) The second quarter of 2013 reflects the gain on the disposal of our Animal Health business (Zoetis).
Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may
not agree to the total for the year.
As of January 31, 2014, there were 195,383 holders of record of our common stock (New York Stock Exchange symbol PFE).